Toronto Metropolitan University
Browse

File(s) not publicly available

Reason: confidential report for collaborator; patent development in consideration

Masafumi compound update (May 2021 report)

report
posted on 2024-10-14, 20:32 authored by Sarah SabatinosSarah Sabatinos, Gillian Okura

Masafumi Compound Update May 18 2021

Compound IC50 values in cancer cell lines (pancreatic- Aspc1, BxPC3, PANC1, PANC 04.03, PANC10.05, HPAC, PANC08.13; and the triple negative MDA-MB-231 breast cancer line). These are compared to Bortezomib/Velcade IC50 of about 1-10 µM, depending on the cell line

Funding

MITACS-Accelerate Industrial R&D Internship Program / Programme de Stage en R&D Industrielle MITACS-Accélération

Natural Sciences and Engineering Research Council

Find out more...

History

Contributor

Sarah Sabatinos

Language

English

Usage metrics

    Chemistry & Biology

    Licence

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC